Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / TAK - Freeline Therapeutics Aims For $100 Million U.S. IPO


TAK - Freeline Therapeutics Aims For $100 Million U.S. IPO

Quick Take

Freeline Therapeutics Holdings plc (FRLN) has filed to raise $100 million in an IPO of its ADSs representing underlying ordinary shares, according to an F-1 registration statement.

The company is a gene therapy biopharma developing treatments for hemophilia B and other serious systemic diseases.

FRLN has produced enviable early Phase 1 / 2 trials results for its lead candidate for the treatment of Hemophilia B.

I look forward to learning more about the IPO in future filings.

Company & Technology

Hertfordshire, UK-based Freeline was founded to develop its AAV-based gene

Read more ...

Stock Information

Company Name: Takeda Pharmaceutical Company Limited American Depositary Shares
Stock Symbol: TAK
Market: NYSE
Website: takeda.com

Menu

TAK TAK Quote TAK Short TAK News TAK Articles TAK Message Board
Get TAK Alerts

News, Short Squeeze, Breakout and More Instantly...